Bioequivalence study of Prazosin 5mg tablet of Amin Pharm Co., IRA
Not Applicable
- Conditions
- Hypertension.Essential (primary) hypertension
- Registration Number
- IRCT20190706044111N27
- Lead Sponsor
- Amin Pharm. Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Aged between 18 - 50 years
Body weight between 50 – 100 kg
Having good health on the basis of medical history and physical & clinical examination
Understand the procedures and give written informed consent
Exclusion Criteria
History of the gastro-intestinal tract surgery
Subject with a history of blood donation or participation in another clinical trial, within the last two months before the first treatment
Subject with a history of drug or alcohol abuse.
Subject who smokes more than 10 cigarettes per day.
Subject with a history of disease leading to using drug within 14 days, or any non-prescription medication within 7 days, before the first treatment.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma concentration of prazosin after single dose of 5mg prazosin tablet. Timepoint: at 0 (before dosing), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0 & 10.0 hr. after dosing. Method of measurement: High Performance Liquid Chromatography (HPLC).
- Secondary Outcome Measures
Name Time Method